Teva Parenteral Medicines Recalls Adrucil
The company voluntarily recalls select lots of Adrucil due to particulate matter.
On May 4, 2015, Teva Parenteral Medicines voluntarily recalled eight lots of Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) because of the potential of particulate matter. The particulates have been identified as aggregates of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. Adrucil is used to manage carcinoma of the colon, rectum, breast, stomach, and pancreas.
Individual recalled vials have the NDC code 0703-3019-11 and the pharmacy shelf pack has the NDC code 0703-3019-12. Teva states that customers should stop use and distribution of the recalled lots and immediately quarantine the product. Use of the recalled lots could result in inflammation, allergic reactions, or blockage of blood vessels and may be life-threatening.
The company reports that it has not received any reports of adverse events and asks patients to contact their healthcare provider if they experience any problems related to the drug. More information on the recalled lots can be found on FDA’s website.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
